Between the Lines
Between the Lines is an engaging 30- to 45-minute open discussion showcasing insightful and impactful perspectives from academic and community oncologists on published, peer-reviewed content.
Anti-HER3 Antibodies May Inhibit Growth of Tumors Harboring NRG1 Fusions
August 20th 2021In this program, D. Ross Camidge, MD, PhD, and Alexander Spira, MD, PhD, discuss a recently published paper on the anti-HER3 monoclonal antibody seribantumab in the treatment of tumor samples with oncogenic NRG1 fusions.
Third-Line Treatment of HER2-Positive Advanced Breast Cancer: From No Standard to A Pandora’s Box
August 9th 2021In this journal club-like program, Sara A. Hurvitz, MD, and Steven E. Vogl, MD, discuss a recently published paper about third-line treatments for HER2-positive breast cancer and provide insight about its implications for clinical practice.
